Arcus Biosciences Inc
$ 21.36
2.79%
11 Feb - close price
- Market Cap 2,571,079,000 USD
- Current Price $ 21.36
- High / Low $ 21.40 / 20.15
- Stock P/E N/A
- Book Value 4.07
- EPS -3.36
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.68 %
- 52 Week High 26.40
- 52 Week Low 6.50
About
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Analyst Target Price
$33.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-06 | 2025-05-06 | 2025-02-19 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-21 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-02-28 |
| Reported EPS | -1.27 | 0 | -1.14 | -1.03 | -1 | -1.02 | -0.05 | -1.08 | -0.94 | -1.04 | -1.09 | -0.93 |
| Estimated EPS | -1.28 | -1.12 | -0.93 | -1.2031 | -1.06 | -1.1 | -0.95 | -1.02 | -1.13 | -1.1 | -1.16 | -1.07 |
| Surprise | 0.01 | 1.12 | -0.21 | 0.1731 | 0.06 | 0.08 | 0.9 | -0.06 | 0.19 | 0.06 | 0.07 | 0.14 |
| Surprise Percentage | 0.7813% | 100% | -22.5806% | 14.3878% | 5.6604% | 7.2727% | 94.7368% | -5.8824% | 16.8142% | 5.4545% | 6.0345% | 13.0841% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.97 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RCUS
2026-02-11 16:57:58
Arcus Biosciences (RCUS) is progressing quemliclustat through a new Phase 1 open-label study to characterize its metabolism, excretion, and mass balance in healthy adult male participants. This study aims to understand how the drug moves through and exits the body, which is crucial for determining safety margins and future dosing in oncology programs. For investors, this methodical advancement de-risks the pipeline, potentially improving sentiment and differentiating Arcus in the immuno-oncology market.
2026-02-10 05:50:37
Arcus Biosciences (RCUS) stock has reached a new 52-week high at $21.03, reflecting strong investor confidence and market momentum with a 67.57% increase over the past year and 132.12% over six months. Despite holding more cash than debt, the company is rapidly burning through cash, with a negative EBITDA of $365 million. Recent developments include an amended loan agreement and varying analyst ratings, with Goldman Sachs upgrading to Buy and Morgan Stanley downgrading to Equalweight.
2026-02-09 14:58:59
Arcus Biosciences (RCUS) stock reached a 52-week high of $21.03, reflecting strong investor confidence and market momentum. The biopharmaceutical company, with a market capitalization of $2.6 billion, has seen its stock price increase significantly over the past year due to advancements in its clinical pipeline and strategic partnerships. Despite concerns about a high cash burn rate, analyst ratings indicate varied price targets, and the company plans to release earnings on February 25.
2026-02-04 21:50:00
This article provides an AI-generated analysis for Arcus Biosciences Inc. (NASDAQ: RCUS), highlighting a weak near and mid-term sentiment despite a long-term positive outlook. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The analysis also emphasizes an exceptional risk-reward short setup.
2026-02-04 14:29:51
Shares of Arcus Biosciences (RCUS) have gained 1.2% in the past four weeks, closing at $21.96, but analysts indicate a potential upside of 57.6%, with a mean estimate of $34.6. This optimistic outlook is further supported by analysts' agreement on higher future earnings, leading to a Zacks Rank #2 (Buy) for RCUS. However, investors are cautioned against solely relying on price targets due to potential biases.
2026-02-03 07:23:34
Arcus Biosciences (NYSE:RCUS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month target price of $30.00. While insiders have recently sold shares totaling approximately $7.09 million, they still retain a significant 9.6% ownership. The clinical-stage biopharmaceutical company, developing cancer immunotherapies, currently has a market capitalization of $2.33 billion.
